Lupin on Wednesday introduced the launch of its
drug below the model identify ‘Covihalt’ for the remedy sufferers with delicate to reasonable
Favipiravir has obtained authorisation from the
Drug Controller Normal of
India (DCGI) for emergency use,
in a regulatory submitting.
Its Covihalt dosage power has been developed retaining
in thoughts comfort of administration, it said, including that the
drug is offered as 200 mg tablets
in the type of a strip of 10 tablets, and priced
Lupin President –
India Area Formulations (IRF) Rajeev Sibal mentioned the corporate believes that it could possibly leverage its experience
in managing widespread group illnesses like tuberculosis to proactively attain sufferers throughout
India and guarantee entry to Covihalt by its sturdy distribution community and subject power.
On August 4, Solar Pharmaceutical Industries had launched
Favipiravir below the model identify ”FluGuard” for the remedy of delicate to reasonable circumstances of
Lupin have been buying and selling 0.32
per cent increased
Rs 943.70 apiece on BSE.